Review



biotinylated human trka  (Carna Inc)


Bioz Verified Symbol Carna Inc is a verified supplier
Bioz Manufacturer Symbol Carna Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Carna Inc biotinylated human trka
    a Structure of PF-07245303. b PF-07245303 co-crystal structure with ITK protein identifying binding sites and docking mode to ITK ATP catalytic site at 1.35 Å (PDB 9NWX). c PF-07245303 binding kinetics to recombinant ITK, <t>TRKA,</t> TRKB, and TRKC protein using SPR. d In vitro absorption, distribution, metabolism, and excretion profile for PF-07245303. e Kinome selectivity for PF-07245303 tested at 1 µM against a panel of 218 kinase constructs colored by percent inhibition in biochemical assays using 1 mM ATP.
    Biotinylated Human Trka, supplied by Carna Inc, used in various techniques. Bioz Stars score: 95/100, based on 23 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+human+trka/TRKA/pmc13100123-287-0-7
    Average 95 stars, based on 23 article reviews
    biotinylated human trka - by Bioz Stars, 2026-11
    95/100 stars

    Images

    1) Product Images from "Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis"

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis

    Journal: Nature Communications

    doi: 10.1038/s41467-026-70000-6

    a Structure of PF-07245303. b PF-07245303 co-crystal structure with ITK protein identifying binding sites and docking mode to ITK ATP catalytic site at 1.35 Å (PDB 9NWX). c PF-07245303 binding kinetics to recombinant ITK, TRKA, TRKB, and TRKC protein using SPR. d In vitro absorption, distribution, metabolism, and excretion profile for PF-07245303. e Kinome selectivity for PF-07245303 tested at 1 µM against a panel of 218 kinase constructs colored by percent inhibition in biochemical assays using 1 mM ATP.
    Figure Legend Snippet: a Structure of PF-07245303. b PF-07245303 co-crystal structure with ITK protein identifying binding sites and docking mode to ITK ATP catalytic site at 1.35 Å (PDB 9NWX). c PF-07245303 binding kinetics to recombinant ITK, TRKA, TRKB, and TRKC protein using SPR. d In vitro absorption, distribution, metabolism, and excretion profile for PF-07245303. e Kinome selectivity for PF-07245303 tested at 1 µM against a panel of 218 kinase constructs colored by percent inhibition in biochemical assays using 1 mM ATP.

    Techniques Used: Binding Assay, Recombinant, In Vitro, Construct, Inhibition

    Effects of PF-07245303 on the kinase activity of human a TRKA, b TRKB, and c TRKC were determined. Graphs of mean % inhibition ± SD at each concentration a n = 5 experiments and b , c n = 4 experiments. PF-07245303 inhibits d TRKA, e TRKB, and f TRKC-dependent phosphorylation in cells expressing human TRKA, TRKB or TRKC and p75. Ligand-induced receptor activation is detected by receptor phosphorylation-induced functional complementation and restored β-galactosidase activity measured by chemiluminescence. Inhibition of d TRKA, e TRKB, and f TRKC activation with PF-07245303 or selective pan-TRK inhibitor PF-06273340. d – f Graph of mean % inhibition ± SD at each concentration across n = 4 experiments. g Determination of PF-07245303 inhibition of TRKA in human blood basophils. Graph of mean % inhibition ± SD of NGF-induced increase in the percent of basophils double positive for CD123 and CD203c at each concentration of PF-07245303 or PF-06273340 across n = 5 donors. h NGF-induced TRKA phosphorylation was measured in human skin sections treated with PF-07245303 (10–0.1 μM) or with 10 μM of PF-06273340 and stimulated with NGF. Representative results for phospho-TRKA activation and mean % inhibition ± SD in skin from one donor. Skin from 3 donors with 6 replicates per condition was evaluated. Comparisons of mean differences = Δ versus control is done by t-test with 113 degrees of freedom, and FDR-adjusted two-sided p -values. 0.1 μM has a Δ = −26.5 a t = −2.28 and p -value = 0.0244. 0.3 μM has a Δ = − 49.8 a t = −4.78 and p -value = 6.58e-06. One micromolar has a Δ = −74.6 a t = −7.18 and p = 1.34e-10. Three micromolar has a Δ = −86.6 a t = −8.33, and p = 5.44e-13. Ten micromolar has a Δ = −93.2 a t = −8.96 and p = 3.91e-14. Notable changes in phospho-TRKA levels relative to vehicle were defined as p < 0.0001 and F < −0.50 and denoted with ***. F = 2 −estimated ΔΔCt treatment difference and F and F 95% CI are in Supplementary Table .
    Figure Legend Snippet: Effects of PF-07245303 on the kinase activity of human a TRKA, b TRKB, and c TRKC were determined. Graphs of mean % inhibition ± SD at each concentration a n = 5 experiments and b , c n = 4 experiments. PF-07245303 inhibits d TRKA, e TRKB, and f TRKC-dependent phosphorylation in cells expressing human TRKA, TRKB or TRKC and p75. Ligand-induced receptor activation is detected by receptor phosphorylation-induced functional complementation and restored β-galactosidase activity measured by chemiluminescence. Inhibition of d TRKA, e TRKB, and f TRKC activation with PF-07245303 or selective pan-TRK inhibitor PF-06273340. d – f Graph of mean % inhibition ± SD at each concentration across n = 4 experiments. g Determination of PF-07245303 inhibition of TRKA in human blood basophils. Graph of mean % inhibition ± SD of NGF-induced increase in the percent of basophils double positive for CD123 and CD203c at each concentration of PF-07245303 or PF-06273340 across n = 5 donors. h NGF-induced TRKA phosphorylation was measured in human skin sections treated with PF-07245303 (10–0.1 μM) or with 10 μM of PF-06273340 and stimulated with NGF. Representative results for phospho-TRKA activation and mean % inhibition ± SD in skin from one donor. Skin from 3 donors with 6 replicates per condition was evaluated. Comparisons of mean differences = Δ versus control is done by t-test with 113 degrees of freedom, and FDR-adjusted two-sided p -values. 0.1 μM has a Δ = −26.5 a t = −2.28 and p -value = 0.0244. 0.3 μM has a Δ = − 49.8 a t = −4.78 and p -value = 6.58e-06. One micromolar has a Δ = −74.6 a t = −7.18 and p = 1.34e-10. Three micromolar has a Δ = −86.6 a t = −8.33, and p = 5.44e-13. Ten micromolar has a Δ = −93.2 a t = −8.96 and p = 3.91e-14. Notable changes in phospho-TRKA levels relative to vehicle were defined as p < 0.0001 and F < −0.50 and denoted with ***. F = 2 −estimated ΔΔCt treatment difference and F and F 95% CI are in Supplementary Table .

    Techniques Used: Activity Assay, Inhibition, Concentration Assay, Phospho-proteomics, Expressing, Activation Assay, Functional Assay, Control

    Related Articles

    Binding Assay:

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis
    Article Snippet: The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions, resulting in 4K–10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis.
    Article Snippet: The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions resulting in 4K-10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Recombinant:

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis
    Article Snippet: The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions, resulting in 4K–10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis.
    Article Snippet: The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions resulting in 4K-10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    In Vitro:

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis
    Article Snippet: The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions, resulting in 4K–10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis.
    Article Snippet: The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions resulting in 4K-10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Construct:

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis
    Article Snippet: The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions, resulting in 4K–10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis.
    Article Snippet: The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions resulting in 4K-10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Inhibition:

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis
    Article Snippet: The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions, resulting in 4K–10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis.
    Article Snippet: The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions resulting in 4K-10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Activity Assay:

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis
    Article Snippet: The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions, resulting in 4K–10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis.
    Article Snippet: The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions resulting in 4K-10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Concentration Assay:

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis
    Article Snippet: The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions, resulting in 4K–10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis.
    Article Snippet: The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions resulting in 4K-10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Phospho-proteomics:

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis
    Article Snippet: The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions, resulting in 4K–10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis.
    Article Snippet: The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions resulting in 4K-10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Expressing:

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis
    Article Snippet: The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions, resulting in 4K–10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis.
    Article Snippet: The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions resulting in 4K-10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Activation Assay:

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis
    Article Snippet: The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions, resulting in 4K–10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis.
    Article Snippet: The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions resulting in 4K-10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Functional Assay:

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis
    Article Snippet: The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions, resulting in 4K–10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis.
    Article Snippet: The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions resulting in 4K-10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Control:

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis
    Article Snippet: The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.The captured ITK was then cross-linked with a 30 s injection of 1:1 pre-mixed NHS/EDC, followed by 30 s of ethanolamine (amine coupling kit, Cytiva), resulting in a level of captured and cross-linked ITK protein ranging from 7K–10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions, resulting in 4K–10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis.
    Article Snippet: The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.The captured ITK was then cross-linked with a 30s injection of 1:1 pre-mixed NHS/EDC, followed by 30s of ethanolamine (amine coupling kit, Cytiva) resulting in a level of captured and cross-linked ITK protein ranging from 7K – 10K RU.. Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions resulting in 4K-10K RU of immobilized TRKA, TRKB, and TRKC proteins.. The following was performed on separate sensor chips containing either ITK or TRK proteins.The following was performed on separate sensor chips containing either ITK or TRK proteins.



    Similar Products

    95
    Carna Inc biotinylated human trka
    a Structure of PF-07245303. b PF-07245303 co-crystal structure with ITK protein identifying binding sites and docking mode to ITK ATP catalytic site at 1.35 Å (PDB 9NWX). c PF-07245303 binding kinetics to recombinant ITK, <t>TRKA,</t> TRKB, and TRKC protein using SPR. d In vitro absorption, distribution, metabolism, and excretion profile for PF-07245303. e Kinome selectivity for PF-07245303 tested at 1 µM against a panel of 218 kinase constructs colored by percent inhibition in biochemical assays using 1 mM ATP.
    Biotinylated Human Trka, supplied by Carna Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+human+trka/TRKA/pmc13100123-287-0-7
    Average 95 stars, based on 1 article reviews
    biotinylated human trka - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    92
    MedChemExpress biotinylated trka
    C-X-C motif chemokine 10 (CXCL10) regulates type 2 alveolar epithelial cell (AEC2) renewal through <t>TrkA.</t> AEC2s cells were isolated from lungs of wild-type (WT) mice 5 days post-bleomycin. TrkA inhibitor ( A ) or p75 inhibitor ( B ) were added to AEC2 cells with or without CXCL10, respectively. Colony numbers were analyzed after 10–14 days of three-dimensional (3-D) gel culture. C : Western blotting analysis of p-TrkA and p-JNK in A549 cells treated with CXCL10 for 30 min or 6 h. The blots were analyzed with anti-p-TrkA, anti-TrkA, anti-p-JNK, anti-JNK, and anti-GAPDH antibodies. p-TrkA, phosphorylated TrkA; p-JNK, phosphorylated JNK. Untreated A549 cells served as a blank control. D : simulated binding curves of different concentrations of CXCL10 to immobilized TrkA. E : steady-state analysis of the binding curves of CXCL10 (from 33 nM to 900 nM) to immobilized TrkA. F : a schematic showing that CXCL10 may recruit T cells through CXCR3, while promote regeneration of AEC2s through TrkA. * P < 0.05, ** P < 0.01. n = 3 replicates for A – B , n =2 replicates for C , Student’s t test for A – C , plotted as means ± SEM.
    Biotinylated Trka, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+human+trka/TrkA%2C+Human/pmc11687959-85-0-4
    Average 92 stars, based on 1 article reviews
    biotinylated trka - by Bioz Stars, 2026-11
    92/100 stars
      Buy from Supplier

    Image Search Results


    a Structure of PF-07245303. b PF-07245303 co-crystal structure with ITK protein identifying binding sites and docking mode to ITK ATP catalytic site at 1.35 Å (PDB 9NWX). c PF-07245303 binding kinetics to recombinant ITK, TRKA, TRKB, and TRKC protein using SPR. d In vitro absorption, distribution, metabolism, and excretion profile for PF-07245303. e Kinome selectivity for PF-07245303 tested at 1 µM against a panel of 218 kinase constructs colored by percent inhibition in biochemical assays using 1 mM ATP.

    Journal: Nature Communications

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis

    doi: 10.1038/s41467-026-70000-6

    Figure Lengend Snippet: a Structure of PF-07245303. b PF-07245303 co-crystal structure with ITK protein identifying binding sites and docking mode to ITK ATP catalytic site at 1.35 Å (PDB 9NWX). c PF-07245303 binding kinetics to recombinant ITK, TRKA, TRKB, and TRKC protein using SPR. d In vitro absorption, distribution, metabolism, and excretion profile for PF-07245303. e Kinome selectivity for PF-07245303 tested at 1 µM against a panel of 218 kinase constructs colored by percent inhibition in biochemical assays using 1 mM ATP.

    Article Snippet: Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions, resulting in 4K–10K RU of immobilized TRKA, TRKB, and TRKC proteins.

    Techniques: Binding Assay, Recombinant, In Vitro, Construct, Inhibition

    Effects of PF-07245303 on the kinase activity of human a TRKA, b TRKB, and c TRKC were determined. Graphs of mean % inhibition ± SD at each concentration a n = 5 experiments and b , c n = 4 experiments. PF-07245303 inhibits d TRKA, e TRKB, and f TRKC-dependent phosphorylation in cells expressing human TRKA, TRKB or TRKC and p75. Ligand-induced receptor activation is detected by receptor phosphorylation-induced functional complementation and restored β-galactosidase activity measured by chemiluminescence. Inhibition of d TRKA, e TRKB, and f TRKC activation with PF-07245303 or selective pan-TRK inhibitor PF-06273340. d – f Graph of mean % inhibition ± SD at each concentration across n = 4 experiments. g Determination of PF-07245303 inhibition of TRKA in human blood basophils. Graph of mean % inhibition ± SD of NGF-induced increase in the percent of basophils double positive for CD123 and CD203c at each concentration of PF-07245303 or PF-06273340 across n = 5 donors. h NGF-induced TRKA phosphorylation was measured in human skin sections treated with PF-07245303 (10–0.1 μM) or with 10 μM of PF-06273340 and stimulated with NGF. Representative results for phospho-TRKA activation and mean % inhibition ± SD in skin from one donor. Skin from 3 donors with 6 replicates per condition was evaluated. Comparisons of mean differences = Δ versus control is done by t-test with 113 degrees of freedom, and FDR-adjusted two-sided p -values. 0.1 μM has a Δ = −26.5 a t = −2.28 and p -value = 0.0244. 0.3 μM has a Δ = − 49.8 a t = −4.78 and p -value = 6.58e-06. One micromolar has a Δ = −74.6 a t = −7.18 and p = 1.34e-10. Three micromolar has a Δ = −86.6 a t = −8.33, and p = 5.44e-13. Ten micromolar has a Δ = −93.2 a t = −8.96 and p = 3.91e-14. Notable changes in phospho-TRKA levels relative to vehicle were defined as p < 0.0001 and F < −0.50 and denoted with ***. F = 2 −estimated ΔΔCt treatment difference and F and F 95% CI are in Supplementary Table .

    Journal: Nature Communications

    Article Title: Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis

    doi: 10.1038/s41467-026-70000-6

    Figure Lengend Snippet: Effects of PF-07245303 on the kinase activity of human a TRKA, b TRKB, and c TRKC were determined. Graphs of mean % inhibition ± SD at each concentration a n = 5 experiments and b , c n = 4 experiments. PF-07245303 inhibits d TRKA, e TRKB, and f TRKC-dependent phosphorylation in cells expressing human TRKA, TRKB or TRKC and p75. Ligand-induced receptor activation is detected by receptor phosphorylation-induced functional complementation and restored β-galactosidase activity measured by chemiluminescence. Inhibition of d TRKA, e TRKB, and f TRKC activation with PF-07245303 or selective pan-TRK inhibitor PF-06273340. d – f Graph of mean % inhibition ± SD at each concentration across n = 4 experiments. g Determination of PF-07245303 inhibition of TRKA in human blood basophils. Graph of mean % inhibition ± SD of NGF-induced increase in the percent of basophils double positive for CD123 and CD203c at each concentration of PF-07245303 or PF-06273340 across n = 5 donors. h NGF-induced TRKA phosphorylation was measured in human skin sections treated with PF-07245303 (10–0.1 μM) or with 10 μM of PF-06273340 and stimulated with NGF. Representative results for phospho-TRKA activation and mean % inhibition ± SD in skin from one donor. Skin from 3 donors with 6 replicates per condition was evaluated. Comparisons of mean differences = Δ versus control is done by t-test with 113 degrees of freedom, and FDR-adjusted two-sided p -values. 0.1 μM has a Δ = −26.5 a t = −2.28 and p -value = 0.0244. 0.3 μM has a Δ = − 49.8 a t = −4.78 and p -value = 6.58e-06. One micromolar has a Δ = −74.6 a t = −7.18 and p = 1.34e-10. Three micromolar has a Δ = −86.6 a t = −8.33, and p = 5.44e-13. Ten micromolar has a Δ = −93.2 a t = −8.96 and p = 3.91e-14. Notable changes in phospho-TRKA levels relative to vehicle were defined as p < 0.0001 and F < −0.50 and denoted with ***. F = 2 −estimated ΔΔCt treatment difference and F and F 95% CI are in Supplementary Table .

    Article Snippet: Biotinylated human TRKA, TRKB, and TRKC proteins (Carna Biosciences) were immobilized onto individual flowcells of a Streptavidin (SA) sensor chip using standard immobilization conditions, resulting in 4K–10K RU of immobilized TRKA, TRKB, and TRKC proteins.

    Techniques: Activity Assay, Inhibition, Concentration Assay, Phospho-proteomics, Expressing, Activation Assay, Functional Assay, Control

    C-X-C motif chemokine 10 (CXCL10) regulates type 2 alveolar epithelial cell (AEC2) renewal through TrkA. AEC2s cells were isolated from lungs of wild-type (WT) mice 5 days post-bleomycin. TrkA inhibitor ( A ) or p75 inhibitor ( B ) were added to AEC2 cells with or without CXCL10, respectively. Colony numbers were analyzed after 10–14 days of three-dimensional (3-D) gel culture. C : Western blotting analysis of p-TrkA and p-JNK in A549 cells treated with CXCL10 for 30 min or 6 h. The blots were analyzed with anti-p-TrkA, anti-TrkA, anti-p-JNK, anti-JNK, and anti-GAPDH antibodies. p-TrkA, phosphorylated TrkA; p-JNK, phosphorylated JNK. Untreated A549 cells served as a blank control. D : simulated binding curves of different concentrations of CXCL10 to immobilized TrkA. E : steady-state analysis of the binding curves of CXCL10 (from 33 nM to 900 nM) to immobilized TrkA. F : a schematic showing that CXCL10 may recruit T cells through CXCR3, while promote regeneration of AEC2s through TrkA. * P < 0.05, ** P < 0.01. n = 3 replicates for A – B , n =2 replicates for C , Student’s t test for A – C , plotted as means ± SEM.

    Journal: American Journal of Physiology - Lung Cellular and Molecular Physiology

    Article Title: CXCR3-independent role of CXCL10 in alveolar epithelial repair

    doi: 10.1152/ajplung.00301.2023

    Figure Lengend Snippet: C-X-C motif chemokine 10 (CXCL10) regulates type 2 alveolar epithelial cell (AEC2) renewal through TrkA. AEC2s cells were isolated from lungs of wild-type (WT) mice 5 days post-bleomycin. TrkA inhibitor ( A ) or p75 inhibitor ( B ) were added to AEC2 cells with or without CXCL10, respectively. Colony numbers were analyzed after 10–14 days of three-dimensional (3-D) gel culture. C : Western blotting analysis of p-TrkA and p-JNK in A549 cells treated with CXCL10 for 30 min or 6 h. The blots were analyzed with anti-p-TrkA, anti-TrkA, anti-p-JNK, anti-JNK, and anti-GAPDH antibodies. p-TrkA, phosphorylated TrkA; p-JNK, phosphorylated JNK. Untreated A549 cells served as a blank control. D : simulated binding curves of different concentrations of CXCL10 to immobilized TrkA. E : steady-state analysis of the binding curves of CXCL10 (from 33 nM to 900 nM) to immobilized TrkA. F : a schematic showing that CXCL10 may recruit T cells through CXCR3, while promote regeneration of AEC2s through TrkA. * P < 0.05, ** P < 0.01. n = 3 replicates for A – B , n =2 replicates for C , Student’s t test for A – C , plotted as means ± SEM.

    Article Snippet: Biotinylated TrkA (Human TrkA, MedChemExpress, Monmouth Junction, NJ; Biotinylation Kit, Genemore, JiangSu) was immobilized onto the streptavidin (SA) tip to probe the interaction between TrkA and CXCL10.

    Techniques: Isolation, Western Blot, Control, Binding Assay